EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Sex differences in treatment allocation and survival in hepatocellular carcinoma: a nationwide population-based cohort study

Ji Won Han, Jeayeon Park, Young Chang, Gwang Hyeon Choi, Jung Hee Kim, Soon Sun Kim, Su Jong Yu, Do Seon Song

The Lancet Regional Health - Western Pacific · 2026-11 · 76 · 102031

DOI: 10.1016/j.lanwpc.2026.102031 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Lancet Regional Health - Western Pacific, 2026-11. Verfasst von Ji Won Han und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Centers for Disease Control and Prevention.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Women with hepatocellular carcinoma (HCC) present with more favorable tumors and better unadjusted survival than men. Whether this advantage persists within stage, and whether aggregate treatment rates obscure sex differences, is uncertain. We examined sex differences in survival within stage and in treatment allocation by age.

Methods

This nationwide population-based cohort study included adults with newly diagnosed HCC in the Korean Primary Liver Cancer Registry (2008–2020) with complete data. Survival was assessed with stage-stratified Kaplan–Meier analyses and sequentially adjusted Cox models. Treatment non-receipt was assessed with case-mix-adjusted logistic regression; a sex-by-age interaction was tested for curative treatment non-receipt in early-stage disease.

Findings

Of 12,118 patients, 2608 (21·5%) were women, who were older but more often had early-stage disease than men (67·1% vs. 55·4%; p < 0·001). During a median follow-up of 106·5 months (IQR 71·0–145·0), 7335 (60·5%) patients died. No statistically significant sex difference in survival was observed within any stage; in the whole cohort, the hazard ratio for death in women was 0·83 (95% CI 0·78–0·88) before and 0·86 (0·81–0·91) after adjustment. Crude treatment non-receipt was similar (13·6% vs. 13·0%; p = 0·43); the adjusted odds ratio in women (1·18, 1·01–1·37) was consistently above 1 across case-mix-adjusted models but not always statistically significant. In early-stage disease, women older than 65 years had higher adjusted odds of curative treatment non-receipt than men (1·27, 1·06–1·52; 1·12, 0·93–1·35, additionally adjusted for liver function and comorbidity), whereas younger women had lower odds (0·84, 0·72–0·98; p for interaction

Förderung

  • Korea Centers for Disease Control and Prevention

Zitieren

APA

Han, J. W., Park, J., Chang, Y., Choi, G. H., Kim, J. H., Kim, S. S., Yu, S. J., & Song, D. S. (2026). Sex differences in treatment allocation and survival in hepatocellular carcinoma: a nationwide population-based cohort study. The Lancet Regional Health - Western Pacific, 76, 102031. https://doi.org/10.1016/j.lanwpc.2026.102031

Vancouver

Han JW, Park J, Chang Y, Choi GH, Kim JH, Kim SS, et al. Sex differences in treatment allocation and survival in hepatocellular carcinoma: a nationwide population-based cohort study. The Lancet Regional Health - Western Pacific. 2026;76:102031. doi:10.1016/j.lanwpc.2026.102031

BibTeX
@article{Han2026,
  author = {Han, Ji Won and Park, Jeayeon and Chang, Young and Choi, Gwang Hyeon and Kim, Jung Hee and Kim, Soon Sun and Yu, Su Jong and Song, Do Seon},
  title = {Sex differences in treatment allocation and survival in hepatocellular carcinoma: a nationwide population-based cohort study},
  journal = {The Lancet Regional Health - Western Pacific},
  year = {2026},
  volume = {76},
  pages = {102031},
  doi = {10.1016/j.lanwpc.2026.102031}
}
Kostenlos starten →